<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218633</url>
  </required_header>
  <id_info>
    <org_study_id>10-003435</org_study_id>
    <nct_id>NCT01218633</nct_id>
  </id_info>
  <brief_title>Dose-response Study of Exendin-9,39 on Glucose Metabolism</brief_title>
  <official_title>A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrian Vella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple studies have examined the effect of endogenous GLP-1 secretions by using a
      competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However,
      the presence of an effect does not necessarily imply that this effect is due to the blockade
      of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic
      concentrations of Exendin may have effects of its own. To examine the effect of Exendin on
      glucose metabolism the investigators propose a dose-response study to determine whether the
      compound has effects in a dose-dependent fashion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>over 360 minutes of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>glucagon secretion</measure>
    <time_frame>over 360 minutes of study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1-(9,36)-amide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-9,39 @30pmol/kg/min</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-9,39 @300pmol/kg/min</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline infusion</intervention_name>
    <description>saline infused at 30ml/hour</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1-9,36 infusion</intervention_name>
    <description>infused @ 1.2pmol/kg/min</description>
    <arm_group_label>GLP-1-(9,36)-amide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin-9,39 at low dose</intervention_name>
    <description>infused at 30pmol/kg/min</description>
    <arm_group_label>Exendin-9,39 @30pmol/kg/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin-9,39 at high dose</intervention_name>
    <description>infused @ 300pmol/kg/min</description>
    <arm_group_label>Exendin-9,39 @300pmol/kg/min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Not on any medication other than thyroid hormone replacement or OCP No history of
        diabetes No prior upper GI surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

